| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
61,398,000 |
| Market
Cap: |
283.66(M) |
| Last
Volume: |
821,939 |
Avg
Vol: |
693,736 |
| 52
Week Range: |
$3.38 - $6.95 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 803 |
| Guru Rank Value : 1 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vanda Pharmaceuticals is a biopharmaceutical company. Co.'s commercial portfolio is comprised of two products, HETLIOZ® for the treatment of Non-24 Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome and Fanapt® for the treatment of schizophrenia. In addition, Co. has a number of drugs in development, including: Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia; and VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
121,098 |
121,098 |
148,134 |
388,157 |
| Total Sell Value |
$513,345 |
$513,345 |
$684,141 |
$2,735,436 |
| Total People Sold |
5 |
5 |
6 |
8 |
| Total Sell Transactions |
10 |
10 |
14 |
33 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gulino Richard L. |
SVP, General Counsel & Sec. |
• – – |
2018-03-01 |
4 |
S |
$18.71 |
$68,473 |
D/D |
(3,660) |
115,073 |
|
- |
|
| Birznieks Gunther |
SVP, Business Development |
• – – |
2018-03-01 |
4 |
S |
$18.72 |
$159,605 |
D/D |
(8,525) |
139,841 |
|
- |
|
| Kelly James Patrick |
EVP & Chief Financial Officer |
• – – |
2018-03-01 |
4 |
S |
$18.72 |
$159,712 |
D/D |
(8,532) |
199,534 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2018-03-01 |
4 |
S |
$18.72 |
$1,141,003 |
D/D |
(60,966) |
1,182,872 |
|
- |
|
| Gulino Richard L. |
SVP, General Counsel & Sec. |
• – – |
2018-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
118,733 |
|
- |
|
| Birznieks Gunther |
SVP, Business Development |
• – – |
2018-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
148,366 |
|
- |
|
| Kelly James Patrick |
EVP & Chief Financial Officer |
• – – |
2018-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
208,066 |
|
- |
|
| Reverberi Gian Piero |
SVP & Chief Commercial Officer |
• – – |
2018-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
140,000 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2018-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
1,243,838 |
|
- |
|
| Kelly James Patrick |
EVP & Chief Financial Officer |
• – – |
2018-01-02 |
4 |
S |
$15.35 |
$140,494 |
D/D |
(9,155) |
168,066 |
|
- |
|
| Kelly James Patrick |
EVP & Chief Financial Officer |
• – – |
2018-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,500 |
177,221 |
|
- |
|
| Gulino Richard L. |
SVP, General Counsel & Sec. |
• – – |
2018-01-02 |
4 |
S |
$15.20 |
$157,565 |
D/D |
(10,367) |
88,733 |
|
- |
|
| Gulino Richard L. |
SVP, General Counsel & Sec. |
• – – |
2018-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
99,100 |
|
- |
|
| Reverberi Gian Piero |
SVP & Chief Commercial Officer |
• – – |
2018-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
110,000 |
|
- |
|
| Birznieks Gunther |
SVP, Business Development |
• – – |
2018-01-02 |
4 |
S |
$15.26 |
$130,777 |
D/D |
(8,568) |
118,366 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2018-01-02 |
4 |
S |
$15.30 |
$2,933,127 |
D/D |
(191,760) |
1,183,838 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2018-01-02 |
4 |
OE |
$0.00 |
$1,440,000 |
D/D |
293,750 |
1,205,373 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2017-12-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
1,031,848 |
|
- |
|
| Bate Kenneth |
Director |
– • – |
2017-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Bate Kenneth |
Director |
– • – |
2017-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Milano Vincent |
Director |
– • – |
2017-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Watkins Thomas |
Director |
– • – |
2017-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Dugan Richard W |
Director |
– • – |
2017-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
10,770 |
|
- |
|
| Cola Michael F |
Director |
– • – |
2017-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Birznieks Gunther |
SVP, Business DevelopmentOffic |
• – – |
2017-03-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
126,934 |
|
- |
|
549 Records found
|
|
Page 9 of 22 |
|
|
0.14 (3.12%) 
